SGEN * Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Seagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3,711.48 |
| 52 Week High | US$3,711.48 |
| 52 Week Low | US$2,994.97 |
| Beta | 0.50 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 14.05% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| SGEN * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 14.0% | 0% | 0% |
Return vs Industry: SGEN * exceeded the MX Biotechs industry which returned -6% over the past year.
Return vs Market: SGEN * exceeded the MX Market which returned 3.7% over the past year.
Price Volatility
| SGEN * volatility | |
|---|---|
| SGEN * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: SGEN * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SGEN *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,256 | David Epstein | www.seagen.com |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.
Seagen Inc. Fundamentals Summary
| SGEN * fundamental statistics | |
|---|---|
| Market cap | Mex$615.62b |
| Earnings (TTM) | -Mex$11.12b |
| Revenue (TTM) | Mex$35.24b |
17.5x
P/S Ratio-55.4x
P/E RatioIs SGEN * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGEN * income statement (TTM) | |
|---|---|
| Revenue | US$2.06b |
| Cost of Revenue | US$1.84b |
| Gross Profit | US$218.75m |
| Other Expenses | US$867.30m |
| Earnings | -US$648.55m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.46 |
| Gross Margin | 10.64% |
| Net Profit Margin | -31.55% |
| Debt/Equity Ratio | 0% |
How did SGEN * perform over the long term?
See historical performance and comparison